Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce A Chabner

Showing results (41-50 of 139) with videos related to

Pageof 14
Sort By:
The Oncologist|September 30, 2008
Preserving the sacred bond: an audit must be performedBruce A Chabner
The Oncologist|June 4, 2017
Regarding "Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies"Bruce A Chabner
The New England Journal of Medicine|March 25, 2011
Early accelerated approval for highly targeted cancer drugsBruce A Chabner
Journal of the National Cancer Institute|January 13, 2016
NCI-60 Cell Line Screening: A Radical Departure in its TimeBruce A Chabner
The Oncologist|February 13, 2016
While We're at It, Let's Whack the FDABruce A Chabner
The Oncologist|October 17, 2012
That old devil moonBruce A Chabner
The Oncologist|December 20, 2002
Pity the poor consumerBruce A Chabner, Dwight Kaufman
The Oncologist|March 2, 2019
Immuno-Oncology in ChinaShun Lu, Bruce A Chabner
The Oncologist|February 4, 2012
Call it cancerBruce A Chabner, Matthew Smith
The Oncologist|August 2, 2011
Patient navigator programs, cancer disparities, and the patient protection and affordable care actBeverly Moy, Bruce A Chabner
Pageof 14

Showing results (41-50 of 139) with videos related to

Sort By:
Pageof 14
The Oncologist|September 30, 2008
Preserving the sacred bond: an audit must be performedBruce A Chabner
The Oncologist|June 4, 2017
Regarding "Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies"Bruce A Chabner
The New England Journal of Medicine|March 25, 2011
Early accelerated approval for highly targeted cancer drugsBruce A Chabner
Journal of the National Cancer Institute|January 13, 2016
NCI-60 Cell Line Screening: A Radical Departure in its TimeBruce A Chabner
The Oncologist|February 13, 2016
While We're at It, Let's Whack the FDABruce A Chabner
The Oncologist|October 17, 2012
That old devil moonBruce A Chabner
The Oncologist|December 20, 2002
Pity the poor consumerBruce A Chabner, Dwight Kaufman
The Oncologist|March 2, 2019
Immuno-Oncology in ChinaShun Lu, Bruce A Chabner
The Oncologist|February 4, 2012
Call it cancerBruce A Chabner, Matthew Smith
The Oncologist|August 2, 2011
Patient navigator programs, cancer disparities, and the patient protection and affordable care actBeverly Moy, Bruce A Chabner
Pageof 14